TNFRSF17 and plasma cell myeloma: Building on these preclinical studies, Xu et al. conducted a first-in-human Phase 1 trial evaluating ESO-T01 product, a lentiviral vector designed to enable in vivo generation of BCMA-targeted CAR-T cells, in patients with R/R multiple myeloma [64].